HERC2P7: A Promising Drug Target / Biomarker (G100132101)

Target Name: HERC2P7

NCBI ID: G100132101

HERC2P7

Other Name(s): HERC2 pseudogene 7

HERC2P7: A Promising Drug Target / Biomarker

HERC2P7 is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell signaling pathways, including the TGF-β pathway. TGF-β is a well-known signaling pathway that plays a crucial role in the development and maintenance of tissues, including muscles, bones, and skin. It is also involved in the regulation of cell growth, differentiation, and survival.

The TGF-β pathway is a complex signaling pathway that is activated by the presence of TGF-β signaling proteins. These proteins include Her2, which is a key component of the pathway. When Her2 is activated, it triggers a series of downstream signaling pathways that result in the production of various proteins that are involved in tissue development and maintenance.

One of the functions of Her2 is to regulate the activity of the transcription factor, p16INK4a. p16INK4a is a key regulator of the TGF-β pathway and is involved in the regulation of cell growth, differentiation, and apoptosis. It is also involved in the development and maintenance of tissues, including muscles, bones, and skin.

In addition to its role in regulating p16INK4a, Her2 is also involved in the regulation of several other genes that are involved in the TGF-β pathway. These genes include SMAD4, which is a transcription factor that is involved in the regulation of gene expression, and CDK4, which is a transcription factor that is involved in the regulation of cell growth and differentiation.

The role of Her2 in the regulation of TGF-β signaling pathways has important implications for the development of cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. The TGF-β pathway is involved in the regulation of cell growth and differentiation, which are processes that are critical for the development and maintenance of tissues.

If the TGF-β pathway is disrupted, it can lead to the development of cancer. For example, studies have shown that changes in the expression of TGF-β signaling proteins, including Her2, have been associated with the development of various types of cancer.

In addition to its role in the regulation of TGF-β signaling pathways, Her2 is also involved in the regulation of cell signaling pathways that are important for the development and maintenance of tissues. These include the Wnt signaling pathway, which is involved in the regulation of cell growth and differentiation, and the Notch signaling pathway, which is involved in the regulation of cell survival and proliferation.

The role of Her2 in the regulation of these signaling pathways has important implications for the development and maintenance of tissues. For example, changes in the expression of Her2 have been associated with the development of various types of diseases, including cancer.

In conclusion, HERC2P7 is a protein that is involved in the regulation of cell signaling pathways that are important for the development and maintenance of tissues. Its role in the regulation of TGF-β signaling pathways, as well as its involvement in the regulation of other signaling pathways, makes it an attractive target for drug development. Further research is needed to fully understand the role of Her2 in the regulation of tissues and the development of cancer.

Protein Name: HERC2 Pseudogene 7

The "HERC2P7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HERC2P7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets